GB201411937D0 - Succinate dehydrogenase inhibitors (SDH's) - Google Patents

Succinate dehydrogenase inhibitors (SDH's)

Info

Publication number
GB201411937D0
GB201411937D0 GBGB1411937.4A GB201411937A GB201411937D0 GB 201411937 D0 GB201411937 D0 GB 201411937D0 GB 201411937 A GB201411937 A GB 201411937A GB 201411937 D0 GB201411937 D0 GB 201411937D0
Authority
GB
United Kingdom
Prior art keywords
sdh
succinate dehydrogenase
dehydrogenase inhibitors
inhibitors
succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1411937.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB1411937.4A priority Critical patent/GB201411937D0/en
Publication of GB201411937D0 publication Critical patent/GB201411937D0/en
Priority to PCT/GB2015/051949 priority patent/WO2016001686A1/en
Priority to EP15736028.0A priority patent/EP3164126B1/en
Priority to CN201580035346.8A priority patent/CN106714793B/zh
Priority to CA2953709A priority patent/CA2953709A1/en
Priority to SG11201610588UA priority patent/SG11201610588UA/en
Priority to JP2016574359A priority patent/JP2017519020A/ja
Priority to AU2015282424A priority patent/AU2015282424A1/en
Priority to US15/322,939 priority patent/US10603298B2/en
Priority to ZA2016/08844A priority patent/ZA201608844B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1411937.4A 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's) Ceased GB201411937D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1411937.4A GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)
US15/322,939 US10603298B2 (en) 2014-07-03 2015-07-03 Succinate dehydrogenase inhibitors (SDHi's)
CA2953709A CA2953709A1 (en) 2014-07-03 2015-07-03 Succinate dehydrogenase inhibitors (sdhi's)
EP15736028.0A EP3164126B1 (en) 2014-07-03 2015-07-03 Succinate dehydrogenase inhibitors
CN201580035346.8A CN106714793B (zh) 2014-07-03 2015-07-03 琥珀酸脱氢酶抑制剂(SDHi’s)
PCT/GB2015/051949 WO2016001686A1 (en) 2014-07-03 2015-07-03 SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)
SG11201610588UA SG11201610588UA (en) 2014-07-03 2015-07-03 SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)
JP2016574359A JP2017519020A (ja) 2014-07-03 2015-07-03 コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ）
AU2015282424A AU2015282424A1 (en) 2014-07-03 2015-07-03 Succinate dehydrogenase inhibitors (SDHi's)
ZA2016/08844A ZA201608844B (en) 2014-07-03 2016-12-21 Succinate dehydrogenase inhibitors (sdhi's)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1411937.4A GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)

Publications (1)

Publication Number Publication Date
GB201411937D0 true GB201411937D0 (en) 2014-08-20

Family

ID=51410633

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1411937.4A Ceased GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)

Country Status (10)

Country Link
US (1) US10603298B2 (enExample)
EP (1) EP3164126B1 (enExample)
JP (1) JP2017519020A (enExample)
CN (1) CN106714793B (enExample)
AU (1) AU2015282424A1 (enExample)
CA (1) CA2953709A1 (enExample)
GB (1) GB201411937D0 (enExample)
SG (1) SG11201610588UA (enExample)
WO (1) WO2016001686A1 (enExample)
ZA (1) ZA201608844B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580328A4 (en) * 2017-02-10 2020-12-30 Health Research, Inc. TARGETING MITOCHONDRIAL II COMPLEX TO REDUCE THE EFFECTS OF CHRONIC HYPOXIA
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
CN112739418A (zh) * 2018-08-21 2021-04-30 美国卫生与公众服务部 使用dsh抑制剂治疗神经损伤和神经障碍的线粒体的代谢调节的方法
CN109793760B (zh) * 2019-02-13 2022-07-19 中国人民解放军总医院 琥珀酸弧菌属在预防或治疗高原病药物中的用途
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
US11813239B2 (en) * 2020-02-18 2023-11-14 Wisconsin Alumni Research Foundation Compositions and methods for improving cardiac structure and/or function
GB202108594D0 (en) 2021-06-16 2021-07-28 Cambridge Entpr Ltd Treatment or prevention of ischaemia reperfusion injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032403B1 (en) 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
WO2005094236A2 (en) 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
NZ575904A (en) 2006-09-28 2011-11-25 Univ Otago Triphenylphosphonium thionitrite nitric oxide donors
WO2011156181A1 (en) * 2010-06-08 2011-12-15 Montefiore Medical Center Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins
WO2013152193A2 (en) 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
US10104882B2 (en) 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities

Also Published As

Publication number Publication date
EP3164126B1 (en) 2021-02-24
SG11201610588UA (en) 2017-01-27
US20170135977A1 (en) 2017-05-18
CN106714793B (zh) 2020-12-01
WO2016001686A1 (en) 2016-01-07
US10603298B2 (en) 2020-03-31
AU2015282424A1 (en) 2017-01-12
JP2017519020A (ja) 2017-07-13
ZA201608844B (en) 2019-04-24
EP3164126A1 (en) 2017-05-10
CN106714793A (zh) 2017-05-24
CA2953709A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
EP3179856A4 (en) Transdermal cannabinoid formulations
EP3219304A4 (en) Moisturizing agent
EP3193600A4 (en) Smyd inhibitors
EP3179819A4 (en) User equipment
EP3116503A4 (en) Hptp-beta inhibitors
EP3195967A4 (en) Drill
EP3174420A4 (en) Injury reduction insole
IL251976A0 (en) Phage therapy
GB201416446D0 (en) New enzyme inhibitor compounds
GB201411937D0 (en) Succinate dehydrogenase inhibitors (SDH's)
EP3110819A4 (en) Heterocyclic compounds
EP3239394A4 (en) Protective clothing
EP3099273A4 (en) Prosthetic sport feet
EP3094286B8 (de) Knöchelmanschette
EP3165200A4 (en) Supporter
EP3169282A4 (en) Prosthetic sport feet
EP3195966A4 (en) Drill
EP3146121A4 (en) Modified pocket former
EP3098298A4 (en) Cell-seeding and -culturing device
SI3220893T1 (sl) Sestavek na osnovi COQ10
EP3197885A4 (en) Heterocyclic compounds and use thereof
EP3096755A4 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
EP3191110A4 (en) Polygalacturonan rhamnogalacturonan1 (pgrg1) composition
EP3040004A4 (en) Pocket tissue
EP3097084A4 (en) New kallikrein 7 inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)